In this MEDtalk professor Stefan Schreiber present a head-to-head study of the efficacy and safety of vedolizumab and adalimumab for treatment over 52 weeks in adults with moderately to severely active ulcerative colitis (UC). The first study to directly compare two biological agents in IBD. Click and hear the results.  

På mindre end 20 minutter kan patienter gennem en app på deres smartphone kan måle fæcescalprotectin i afføringen og dermed sygdomsaktivitet ved henholdsvis morbus Crohn og colitis ulcerose. Snart bliver det også mulig at anvende en app ved irritabel tyktarm. Klik og hør Pia Munkholm fortælle om, hvor enkelt det er at anvende app’en.

This study addresses whether existing transcriptional profile scan improve and support the current definition of UC in remission apart from the today existing endoscopic, histological and laboratory scoring systems. In this MEDtalk Ruth Paulssen tells og presents that a gut–brain communication network is involved during remission beside the partial restoration of immunological functions and recovery of local homeostasis in the epithelial mucus layer and lamina propria. Inaddition, a certain role for the composition ofbacterial gut flora may be implied.  

MEST SETE MEDtalks

ECCO 2019: Prevalence and healthcare costs of perianal fistulas in Crohn’s disease   Se hele webinar

ECCO 2019: Prevalence and healthcare costs of perianal fistulas in Crohn’s disease

<script src="https://fast.wistia.com/embed/medias/b5rwewng4t.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_b5rwewng4t seo=false videoFoam=true" style="height:100%;position:relative;width:100%"><div class="wistia_swatch" style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;"><img src="https://fast.wistia.com/embed/medias/b5rwewng4t/swatch" style="filter:blur(5px);height:100%;object-fit:contain;width:100%;" alt="" onload="this.parentNode.style.opacity=1;" /></div></div></div></div>
ECCO 2019: Prevalence and healthcare costs of perianal fistulas in Crohn’s disease&nbsp;&nbsp;&nbsp;<a href='https://bestprac.dk/webinar/ecco-2019-prevalence-and-healthcare-costs-of-perianal-fistulas-in-crohns-disease/'>Se hele webinar
Prevalence and healthcare costs of perianal fistulas in Crohn’s disease

ECCO 2019: Kræftrisiko ved IBD opstået i barndommen

<script src="https://fast.wistia.com/embed/medias/b5rwewng4t.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_b5rwewng4t seo=false videoFoam=true" style="height:100%;position:relative;width:100%"><div class="wistia_swatch" style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;"><img src="https://fast.wistia.com/embed/medias/b5rwewng4t/swatch" style="filter:blur(5px);height:100%;object-fit:contain;width:100%;" alt="" onload="this.parentNode.style.opacity=1;" /></div></div></div></div>
ECCO 2019: Kræftrisiko ved IBD opstået i barndommen&nbsp;&nbsp;&nbsp;<a href='https://bestprac.dk/webinar/ecco-2019-ibd-cancer-and-serious-infections-in-europe-i-care-study-2/'>Se hele webinar
Kræftrisiko ved IBD opstået i barndommen

ECCO 2019: Treatment of IBD with thiopurine and allopurinol vs thiopurine monotherapy

<script src="https://fast.wistia.com/embed/medias/b5rwewng4t.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_b5rwewng4t seo=false videoFoam=true" style="height:100%;position:relative;width:100%"><div class="wistia_swatch" style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;"><img src="https://fast.wistia.com/embed/medias/b5rwewng4t/swatch" style="filter:blur(5px);height:100%;object-fit:contain;width:100%;" alt="" onload="this.parentNode.style.opacity=1;" /></div></div></div></div>
ECCO 2019: Treatment of IBD with thiopurine and allopurinol vs thiopurine monotherapy&nbsp;&nbsp;&nbsp;<a href='https://bestprac.dk/webinar/ecco-uc-and-cd-increased-the-risk-of-type-2-diabetes-2-3-2/'>Se hele webinar
Treatment of IBD with thiopurine and allopurinol vs thiopurine monotherapy

ECCO 2019: Vedolizumab vs adalimumab in patients with active ulcerative colitis

<script src="https://fast.wistia.com/embed/medias/b5rwewng4t.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_b5rwewng4t seo=false videoFoam=true" style="height:100%;position:relative;width:100%"><div class="wistia_swatch" style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;"><img src="https://fast.wistia.com/embed/medias/b5rwewng4t/swatch" style="filter:blur(5px);height:100%;object-fit:contain;width:100%;" alt="" onload="this.parentNode.style.opacity=1;" /></div></div></div></div>
ECCO 2019: Vedolizumab vs adalimumab in patients with active ulcerative colitis&nbsp;&nbsp;&nbsp;<a href='https://bestprac.dk/webinar/ecco-2019-vedolizumab-vs-adalimumab-in-patients-with-active-ulcerative-colitis/'>Se hele webinar
Vedolizumab vs adalimumab in patients with active ulcerative colitis

Previous reports have indicated that the treatment of patients with elderly-onset IBD, defined as patients diagnosed ≥60 years, differs from that of younger patients. This study aimed to assess the treatment of elderly-onset IBD during the first 3 years of follow-up, compared with IBD diagnosed in patients aged 15–39 and 40–59, in a European population-based inception cohort. Click and hear Natalia Pedersen present the result

Is there a connection between biomarkers of collagen degradation and formation and disease activity in patients with Crohn's disease, and can these biomarkers be used in monitoring and prediction of disease activity and in differentiation between patients with CD and healthy individuals? Click and hear Joachim Hoeg Mortensen give the answer.

Thiopurine and allopurinol combination therapy is associated with clinical remission in patients with IBD, but its influence on adverse outcomes. In this study Sandra Bohn Thomsen et al. compared patients with IBD treated with thiopurine and allopurinol and patients with IBD treated with thiopurine monotherapy. Click and hear the result.

#Seneste udgivelse

Gastroenterologi

NR. 6 • marts 2019
3. Årgang
  • Kolorektalcancer
  • Fistler ved morbus Crohn
  • Cøliaki